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Background: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world. Hydrogen
sulfide (H2S) plays an important role in physiology and pathophysiology of liver. However, whether exogenous H2S
could mitigate the hepatic steatosis in mice remains unclear. The aim of this study is to evaluate the effects of H2S
on fatty liver.
Methods: C57BL/6 mice were fed with either a high-fat diet (HFD) or a normal fat diet (NFD) for 16 weeks. After
12 weeks of feeding, the HFD-fed mice were injected one time per day with NaHS or saline for the followed
4 weeks.
Results: Compared to NFD, HFD could induce an accumulation of lipids in liver and a damage of hepatic structure.
Compared to saline treatment, in the liver of HFD fed mice H2S treatment could significantly (1) recover the
structure; (2) decrease the accumulation of lipids including triglyceride (TG) and total cholesterol (TC); (3) decrease
the expression of fatty acid synthase (FAS) and increase the expression of carnitine palmitoyltransferase-1 (CPT-1);
(4) reduce malondialdehyde (MDA) levels; (5) increase the activities of superoxide dismutase (SOD) and glutathione
peroxidase (GPx).
Conclusion: H2S could mitigate the fatty liver by improving lipid metabolism and antioxidant potential in HFD-induced
obese mice.
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Nonalcoholic fatty liver disease (NAFLD) is the most
common liver disease in the world, which is caused by
abnormal accumulation of triglyceride inside the hepato-
cytes [1]. NAFLD may progress to non-alcoholic steato-
hepatitis (NASH), fibrosis, cirrhosis, and hepatocellular
cancer, and is also a risk factor for the development of
type 2 diabetes and cardiovascular disease (CVD) [2].
Hydrogen sulfide (H2S) is an endogenous signaling mol-
ecule in mammalians [3], which is synthesized enzymatically* Correspondence: xuemengzhou@henu.edu.cn; ailingji@163.com;
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unless otherwise stated.by cystathionine β-synthase (CBS), cystathionine γ-lyase
(CSE), and 3-mercaptopyruvate sulfurtransferase (MST)
during cysteine metabolism [3]. Accumulating evidence
suggests that H2S plays an important role in physiology
and pathophysiology of liver [4]. The dysregulation of en-
dogenous H2S is correlated with the symptoms of diabetes
[5,6] and liver cirrhosis [7]. Blood levels of H2S in type 2
diabetic patients (T2D) are lower than that of the controls
[8]. Endogenous formation of H2S is impaired in rats with
NASH and treatment with H2S can prevent NASH in rats
possibly through abating oxidative stress and suppressing
inflammation [9]. The administration of sodium hydro-
sulfide (NaHS)-a H2S donor in rodents protects
against liver injury [4], which is induced by ischemia
reperfusion [10], acetaminophen [11], or carbon tetra-
chloride [7]. Application of H2S also exhibits the effectsOpen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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[14,15], apoptosis [16], inflammation [17], angiogenesis
[18-20], and blood pressure [21-23].
Recent studies have demonstrated that CSE, CBS, and
MST proteins could be detected in the liver, and they con-
tribute to liver production of H2S to different extents
[4,9,24-26]. High fat diet can induce a down-regulation of
CSE/CBS and results in less H2S production in the liver
of rodents [25]. Based on this point, we propose that in-
creasing H2S by administration of NaHS may restore liver
from steatosis in HFD-induced obese mice. To prove our
hypotheses, we employed a diet-induced obesity (DIO)
mouse model to evaluate the effects of exogenous H2S on
fatty liver of obese mice. We found that the administration
of H2S donor NaHS could mitigate the fatty liver by im-
proving lipid metabolism and antioxidant potential in
HFD-induced obese mice. H2S products may be used as
therapeutical drugs for the NAFLD.
Materials and methods
Animals
The protocols for animal experiments were reviewed
and approved by the Animal Care and Use Committee
of Henan University. Eight weeks old male C57BL/6
mice were purchased from Nanjing Biomedical Research
Institute of Nanjing University (Nanjing, China) and
housed in a temperature and humidity controlled envir-
onment on a 12 hour light/dark cycle with free access to
food and water. The mice were fed either a chow (nor-
mal fat diet, NFD; KeAoXieli, Beijing, China) or a high
fat diet (HFD, 45% kcal as fat, MD12032, Medicience
Ltd., Jiangsu, China) for total 16 weeks. After 12 weeks
of feeding, the HFD feeding mice were divided into HFD
group and HFD +H2S group. Each group contained 10
HFD feeding mice. The mice from HFD group and HFD+
H2S group were received an intraperitoneal (i.p.) injection
of either saline (10 ml/kg/day) or NaHS (50 umole/kg/day,
dissolved in saline, 10 ml/kg body weight) for 4 weeks.
At the end of experiments, the mice were killed. Tissues
were rapidly removed from the mice and frozen either in
liquid nitrogen or embedded in frozen section compound
(Surgipath FSC22, Leica) and stored at −20°C or by
immersion in 4% formalin.
Histological analysis
For histology, livers were fixed in formalin, embedded in




CPT-1 CCAGGCTACAGTGGGACATTof livers were stained with hematoxylin and eosin. For
oil red O (ORO) staining, the frozen liver tissues were
cut into 10 μm-thick sections, stained with oil red O, and
counterstained with hematoxylin [27]. All sections were
scanned at an absolute magnification of 200× under a
light microscope (Olympus, BX51 microscope, Tokyo,
Japan) and analyzed using Image-J software (NIH). The
accumulation of hepatic lipid droplets was presented as
the percentage of the blank area (lipid droplets, H&E
staining) or the red staining area (lipid droplets, ORO stain-
ing) relative to the whole area of the photomicrograph.
Determination of liver triglyceride (TG) and total
cholesterol (TC)
Liver tissues were homogenized on ice with the sample
buffer [tissue weight: buffer = 1(g): 9(ml)]. The homoge-
nates were centrifuged at 2500 rpm for 10 min. The su-
pernatants were transferred to the new tubes. Triglyceride
(TG) and total cholesterol (TC) in the supernatants were
measured by enzymatic colorimetric methods using com-
mercial kits according to the manufacturer’s protocols
(Nanjing Jiancheng Bioengineering Institute, Nanjing,
China).
RNA extraction and real-time PCR
Total RNA was isolated from liver tissues using TRIzol
reagent (life technologies), treated with DNase I (Roch),
and purified using an RNA Clean Up Kit (Kangwei, China).
One microgram of total RNA was used for cDNA synthesis
using a cDNA Reverse Transcription Kit (Kangwei, China).
The primer sequences for fatty acid synthase (FAS) [28],
carnitine palmitoyltransferase-1 (CPT-1) [29], and 18s
rRNA [30] are shown in Table 1. PCR tests were per-
formed in a total volume of 20 μl using the following
thermal cycling parameters: 94°C for 2 min, and then
40 cycles of 94°C for 30s, 58°C for 30s, and 72°C for 1 min.
The mRNA expression levels of the test genes were normal-
ized to 18s rRNA levels.
Measurement of hepatic FAS and CPT-1 levels
A small piece of the frozen liver tissue was homogenized
in PBS (pH 7.2-7.4) on ice by manual grinding. Insoluble
material was removed by centrifugation for 15 min at
2000 rpm, 4°C. Hepatic FAS and CPT-1 levels were mea-
sured using ELISA kits according to the manufacturer’s




Wu et al. Medical Gas Research  (2015) 5:1 Page 3 of 8Determination of hepatic lipid peroxidation and
antioxidant enzymes
Malondialdehyde (MDA) is a product of the lipid peroxi-
dation and frequently used as a biomarker of oxidative
stress [31]. In present study, the lipid peroxidation was
determined by measuring the formation of thiobarbituric
acid-reactive substances (TBARS) spectrophotometric-
ally, and expressed as malondialdehyde (MDA) concentra-
tion [32]. The production of MDA, and activities of
glutathione peroxidase (GPx), catalase (CAT), total
superoxide dismutase (T-SOD), Cu/Zn-SOD, and Mn-SOD
in liver tissues were measured with assay kits according to
the instructions of manufacturer (Nanjing Jiancheng
Bioengineering Institute, Nanjing, China).
Statistical analysis
Data were presented as means ± standard error of mean
(SEM). Differences between groups were analyzed by
one-way analysis of variance (ANOVA) using SPSS 17.0
software, followed by Tukey’s test. A value of P < 0.05
was considered significant.
Results
H2S decreases the liver weights of obese mice
After 16 weeks feeding, the mice were killed and the wet
weight of the liver was monitored. Compared to the
NFD fed mice, HFD fed mice showed increased liver
weight (Figure 1A, P < 0.01). H2S administration tended
to significantly lower the liver weight compared to HFD
group (Figure 1A, P < 0.05). HFD feeding did not affect
the liver/body weight ratio (Figure 1B). H2S treatment
markedly reduced the liver/body weight ratio (Figure 1B,
P < 0.05).
H2S reduces the accumulation of lipids in the liver of
obese mice
Representative photomicrographs of liver H&E as well
as ORO staining and quantitative analysis of hepaticFigure 1 Effects of H2S on the liver mass of HFD-induced obese mice
are means ± SEM (n = 10).*p < 0.05, **p < 0.01 vs. HFD group.triglyceride content were shown in Figure 2. Compared
to NFD group, HFD caused significant vacuolar degener-
ation of hepatocytes, disruption of normal hepatic lob-
ules, and inflammatory cells infiltration in H&E-stained
liver sections (Figure 2A). HFD-induced fat accumula-
tion was characterized mainly by microvesicular steatosis
as shown by ORO staining (Figure 2A), suggesting im-
paired mitochondrial function [33]. Compared to HFD
group, H2S treatment significantly reduced hepatic
lipid droplets and macrovesicular steatosis (Figure 2B,
C, P < 0.01). Furthermore, the contents of TG and TC
were analyzed to determine the extent of lipid accu-
mulation in the liver. As shown in Figure 2D and 2E,
HFD-fed mice had increased TG and TC contents in
the liver compared to that of NFD group, while H2S
treatment markedly reduced hepatic TG and TC con-
tents (P < 0.05). These results suggest that H2S may
restore the liver from hepatic steatosis in obese mice.
H2S modulates the expression of hepatic FAS and CPT-1
FAS and CPT are two representative enzymes involved
in lipid biogenesis and energy expenditure [33]. The ex-
pression levels of FAS and CPT-1 were assessed to in-
vestigate whether H2S would affect lipid metabolism in
the liver. Although high-fat feeding markedly increased
the mRNA expression level of FAS (Figure 3A, B, P < 0.05),
there was no significant change in FAS protein expression
between the NFD and HFD groups (Figure 3D). Compared
to HFD group, H2S treatment reduced FAS expression
at both the mRNA and protein levels (Figure 3A, B, D,
P < 0.05). The mRNA and protein expression levels of
CPT-1 were significant lower in HFD group than that
in NFD group (Figure 3A, C, E, P < 0.01), while H2S
treatment increased CPT-1 expression significantly at
both the mRNA and protein levels (Figure 3A, C, E,
P < 0.05). Down-regulation of FAS in liver indicates
that the synthesis of lipids decreased. Up-regulation of
CPT-1 suggests that the expenditure of lipids increased.. (A) Liver weight. (B) The ratio of liver weight vs body weight. Data
Figure 2 Effects of H2S on HFD-induced hepatic steatosis in mice. (A) Representative images of H&E and ORO staining of liver sections
(200×). (B-C) The quantification of the hepatic lipid droplets accumulation was presented as the percentage of the blank area (lipid droplets, H&E
staining) or the red staining area (lipid droplets, ORO staining) relative to the whole area of the photomicrograph. (D-E) Hepatic triglyceride and
total cholesterol levels. Data are means ± SEM (n = 10). *p < 0.05, **p < 0.01 vs HFD group.
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of lipids in liver possibly through down-regulation of FAS
and up-regulation of CPT-1.
H2S regulates lipid peroxidation and antioxidant enzyme
activities in liver
HFD feeding significantly increased hepatic MDA for-
mation (end-product of lipid peroxidation, as a bio-
marker of oxidative stress) and suppressed the activitiesof hepatic antioxidant enzymes including GPx, T-SOD,
Cu/Zn-SOD, and Mn-SOD. H2S treatment markedly de-
creased hepatic MDA formation and restored the activ-
ities of hepatic GPx, T-SOD, Cu/Zn-SOD, and Mn-SOD
(Figure 4A, B, D, E, F, P < 0.05). No significant differ-
ences were observed in the catalytic activity of CAT
among groups, suggesting that HFD feeding and H2S
treatment did not affect the activity of CAT (Figure 4C).
These results suggest that H2S protects the liver injury
Figure 3 Effects of H2S on mRNA and protein levels of FAS and CPT-1 in the liver of HFD-fed mice. (A-C) The mRNA levels of
FAS and CPT-1 were examined by RT-PCR (n = 3). (D-E) The protein levels of FAS and CPT-1 were examined by ELISA (n = 10). Data are
means ± SEM. *p < 0.05, **p < 0.01 vs HFD group.
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stress and increasing the activities of the antioxidant en-
zymes in the liver of HFD fed mice.
Discussion
The present study was designed to determine the effects
of H2S on hepatic steatosis using a mouse model of
HFD-induced obesity. We found that the administration
of H2S donor NaHS could (1) reduce the liver weight;
(2) reduce the contents of TG and TC in hepatocytes;
(3) increase CPT-1 expression and decrease FAS expres-
sion; (4) increase the activities of antioxidant enzymes
such as SOD and GPx. Based on our findings, we pro-
posed a possible mechanism of H2S in mitigating fatty
liver as shown in Figure 5. H2S can restore the liverfrom steatosis through suppressing hepatic fat accumula-
tion by down-regulation of FAS and up-regulation of
CPT-1. Additionally, H2S mitigates the fatty liver through
up-regulating the activities of antioxidant enzymes (GPx
and SOD). Take together, H2S products may be used as a
therapeutical drug for the NAFLD.
Previous studies have demonstrated that a dramatic in-
crease in overall liver weight and/or liver/body weight ratio
could be observed in obese mice [34,35]. In the current
study, HFD feeding resulted in a significant increase in
overall liver weight, but did not change the liver/body
weight ratio. However, H2S administration significantly re-
duced both the liver weight and liver/body weight ratio.
Taken together, our results demonstrate that H2S has the
ability to decrease liver weight in HFD-fed mice.
Figure 4 Effects of H2S on the MDA levels and the activities of antioxidant enzymes in the liver of HFD-fed mice. (A) MDA levels.
(B-F) The activities of GPx, CAT, total SOD, Cu/Zn-SOD, and Mn-SOD. Data are means ± SEM (n = 10). *p < 0.05, **p < 0.01 vs HFD group.
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in various aspects of lipid and glucose metabolism in re-
sponse to nutritional and hormonal signals [4,36]. Liver
dysfunction could lead to dysregulation of lipid metabol-
ism, including alterations in fatty acid biosynthesis,
beta-oxidation and very low density lipoprotein (VLDL)
secretion, which subsequently influences serum levels of
cholesterol and lipoproteins [4,37,38]. In the present study,
our observation proved obvious fat accumulation in
the liver after feeding of mice with 45% HFD for 16 weeks,
which was evidenced by H&E and ORO staining (Figure 2).
These phenotypic alterations were clearly abolished by
H2S treatment for 4 weeks. In addition, H2S adminis-
tration significantly reduced the hepatic triglyceride
and cholesterol levels in HFD-induced obese mice,
which was similar to a previous study that it inhibitedcholesterol and triglyceride synthesis in liver of MCD
diet-fed rats [9].
FAS and CPT-1 are two representative enzymes which
play important roles in lipid biogenesis and energy ex-
penditure [33]. FAS could effectively convert acetyl-CoA
and malonyl-CoA into palmitate in a process that re-
quires NADPH, which is supplied by both the pyruvate
cycle and the pentose phosphate pathway [39]. CPT-1,
an enzyme that resides in the outer mitochondrial mem-
brane, is responsible for facilitating the entry of fatty
acids into the mitochondria for oxidation [40,41]. In this
study, H2S treatment markedly reduced FAS expression
at both the mRNA and protein levels compared to the
HFD group. In contrast, the increased expression of
CPT-1 was observed in HFD +H2S group. These results
suggest that H2S might prevent the development of fatty
Figure 5 Effects of H2S on fatty liver. H2S mitigates fatty liver
by improving lipid metabolism and antioxidant potential. H2S,
hydrogen sulfide; FAS, fatty acid synthase; CPT-1, carnitine
palmitoyltransferase-1; CAT, catalase; SOD, superoxide dismutase;
GPx, glutathione peroxidase. ↓ shows decrease; ↑ shows
increase; → shows no obvious change.
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regulating enzymes.
Reactive oxygen species (ROS) are free radicals derived
from oxygen and non-radical species such as hydrogen
peroxide (H2O2) [42]. Under normal physiological con-
ditions, the levels of ROS generated from the oxidative
processes within the cell can be effectively reduced by
the antioxidant defense systems, which represent a num-
ber of enzymes such as SOD, CAT, and GPx, as well as
non-enzymes include glutathione (GSH), vitamin E, vita-
min A, and vitamin C [43,44]. Recent studies have indi-
cated that ROS plays an important role in various liver
diseases as a significant causative factor, including NAFLD/
NASH [43,45,46]. Oxidative stress is defined as an imbal-
ance between the formation of ROS and the antioxidant
defense capacity [47]. A central measurement of oxidative
stress is lipid peroxidation (LPO), as indicated by MDA
levels, which can contribute to a consequence of cellular
damage [44]. It has been reported that H2S could prevent
the elevation of MDA induced by MCD feeding [9]. Our
results showed that H2S treatment significantly decreased
hepatic MDA formation in HFD group. On the other hand,
our present study found HFD diet declined hepatic anti-
oxidative defense via down-regulating the activities of GPx
and SOD. H2S effectively restored the activities of theseenzymes. These findings indicate that H2S could provide
anti-oxidative effects against HFD-induced hepatotoxicity.
Based on the results obtained in the present study, it
is concluded that administration of H2S could mitigate
the fatty liver by suppressing hepatic fat accumulation
through down-regulation of FAS and up-regulation of
CPT-1 in HFD-fed obese mice. In addition, H2S may
suppress oxidative stress by increasing the activities of
antioxidant enzymes such as GPx and SOD. These re-
sults suggest that H2S can play an important role in
regulating the lipid and antioxidant metabolism. How-
ever, further studies are needed to elucidate the precise
underlying mechanism of lipid metabolism and antioxi-
dant activities of H2S.
Conclusion
In conclusion, we proved that H2S can restore the liver
from steatosis in obese mice. As shown in Figure 5, H2S
mitigates the fatty liver most likely through (1) suppress-
ing hepatic fat accumulation by down-regulation of FAS
and up-regulation of CPT-1; (2) up-regulating the activ-
ities of antioxidant enzymes (GPx and SOD).
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